oHSV2 was efficacious against a treated subcutaneous CT26 tumor and demonstrated a systemic immune response against non-injected tumors, which was associated with increased NK, CD8+ T, and dendritic cells in the tumor [19]. Here, CD8A is linked to neoplasm.